Acceptability of Switching to Long-Acting Cabotegravir and Rilpivirine Among People Living with HIV on Dolutegravir/Rilpivirine Combination: A Single-Center Experience

被引：0
|
作者：
Castelli, Alessandro [1 ]
Lanzafame, Massimiliano [1 ,4 ]
Morra, Matteo [2 ]
Bertoldi, Marco [1 ]
Delama, Andrea [1 ]
Fait, Daniela [1 ]
Vento, Sandro [3 ]
机构：
[1] Santa Chiara Hosp, Dipartimento Area Med, Unit Infect Dis, Trento, Italy
[2] Azienda Osped Univ Integrata, GB Rossi Hosp, Unit Infect Dis, Verona, Italy
[3] Univ Puthisastra, Fac Med, Phnom Penh, Cambodia
[4] Via Str Romana 11, I-37047 Verona, San Bonifacio, Italy
来源：
AIDS RESEARCH AND HUMAN RETROVIRUSES | 2024年 / 40卷 / 05期
关键词：
HIV; long-acting cabotegravir; rilpivirine; dolutegravir; stigma;
D O I：
10.1089/aid.2023.0070
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The availability of long-acting cabotegravir and rilpivirine injection combination requires some changes in service delivery of outpatient HIV clinics; it is therefore important for clinicians to know the potential number of people living with HIV (PLWH) who are interested in a long-acting antiretroviral treatment. We aimed to determine in an outpatient clinic the number of PLWH, on dolutegravir/rilpivirine, accepting a switch to an injectable long-acting antiretroviral treatment, and the reasons underlying this choice. In our single-center study, in this subset of HIV-infected patients, the main cause for refusal of a long-acting injectable regimen was the need for the administration to be done in hospital, as required in Italy, suggesting that current regulations about this aspect must be changed.
引用
收藏
页码：283 / 285
页数：3
相关论文
共 50 条
  • [21] A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
    Bares, Sara H.
    Scarsi, Kimberly K.
    CURRENT OPINION IN HIV AND AIDS, 2022, 17 (01) : 22 - 31
  • [22] Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong
    Chan, M. C. J.
    Chik, S. H. T.
    Lamb, S. S.
    Choi, Y. C. C.
    Lau, W. T. A.
    Leung, C. S. E.
    To, P. Y. L.
    Lau, P. L. D.
    Tsang, T. Y. O.
    HIV MEDICINE, 2023, 24 : 155 - 156
  • [23] Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
    Orkin, Chloe O. C.
    Arasteh, Keikawus A. K.
    Hernandez-Mora, M. Gorgolas M. G. H. M.
    Pokrovsky, Vadim P. V.
    Overton, Edgar T. O. E. T.
    Girard, Pierre-Marie G. P. M.
    Oka, Shinichi O. S.
    Walmsley, Sharon W. S.
    Bettacchi, Chris B. C.
    Brinson, Cynthia B. C.
    Philibert, Patrick P. P.
    Lombaard, Johan L. J.
    Clair, Marty C. M.
    Crauwels, Herta C. H.
    Ford, Susan L. F. S. L.
    Patel, Parul P. P.
    Chounta, Vasiliki C. V.
    D'Amico, Ronald D. R.
    Vanveggel, Simon V. S.
    Dorey, David D. D.
    Cutrell, Amy C. A.
    Griffith, Sandy G. S.
    Margolis, David A. M. D. A.
    Williams, Peter E. W. P. E.
    Parys, Wim P. W.
    Smith, Kimberly Y. S. K. Y.
    Spreen, William R. S. W. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1124 - 1135
  • [24] Letter to the Editor: Real-Life Experience of Long-Acting Cabotegravir-Rilpivirine Combination in a Person Living with HIV with Detectable Viremia: A Case Report
    Ciccullo, Arturo
    Iannone, Valentina
    Lombardi, Francesca
    Borghetti, Alberto
    Di Giambenedetto, Simona
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2024, 40 (10) : 555 - 556
  • [25] Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV
    Mazzitelli, Maria
    Agostini, Elena
    Vania, Eleonora
    Presa, Nicolo
    Sasset, Lolita
    Leoni, Davide
    Gardin, Samuele
    Scaglione, Vincenzo
    Cattelan, Annamaria
    HIV RESEARCH & CLINICAL PRACTICE, 2024, 25 (01)
  • [26] Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV
    Mazzitelli, M.
    Agostini, E.
    Rossetto, A.
    Vania, E.
    Sasset, L.
    Leoni, D.
    Gardin, S.
    Scaglione, V.
    Cattelan, A.
    HIV MEDICINE, 2023, 24 : 83 - 84
  • [27] Long-acting cabotegravir plus rilpivirine for HIV treatment: FLAIR week 96 results
    Orkin, C.
    Oka, S.
    Philibert, P.
    Brinson, C.
    Bassa, A. C.
    Gusev, D.
    Degen, O.
    Gonzalez Garcia, J.
    D'Amico, R.
    Dorey, D.
    Griffith, S.
    Margolis, D. A.
    St Clair, M.
    Williams, P.
    Spreen, W. R.
    HIV MEDICINE, 2020, 21 : 14 - 14
  • [28] Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine
    Alagaratnam, Jasmini
    Kelly, Niall
    Dustan, Simon
    Naous, Nadia
    Nwanbila, Modest
    Byrne, Ruth
    Girometti, Nicolo
    Asboe, David
    Taylor, Graham P.
    Boffito, Marta
    AIDS, 2025, 39 (01) : 95 - 98
  • [29] Eligibility for long-acting cabotegravir/rilpivirine in youth aged 12-25 living with perinatally acquired HIV
    Ryan, Fionnuala
    Mackie, Nicola E.
    Jayadel, Hana
    Ayers, Sara
    Foster, Caroline
    HIV MEDICINE, 2023, 24 : 16 - 16
  • [30] Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida
    Fisk-Hoffman, Rebecca J.
    Ranger, Sashaun S.
    Gracy, Abigail
    Gracy, Hannah
    Manavalan, Preeti
    Widmeyer, Maya
    Leeman, Robert F.
    Cook, Robert L.
    Canidate, Shantrel
    AIDS PATIENT CARE AND STDS, 2024, 38 (06) : 275 - 285
12345